H.R. 1230: Bone Marrow Failure Disease Research and Treatment Act

H.R. 1230

Bone Marrow Failure Disease Research and Treatment Act

Sponsor
Rep. Doris O. Matsui

Date
September 29, 2010 (111th Congress, 2nd Session)

Staff Contact
Communications

Floor Situation

H.R. 1230 is expected to be considered on the House floor on Wednesday, September 29, 2010, under a suspension of the rules, requiring a two-thirds majority vote to pass.  Rep. Matsui (D-CA) introduced H.R. 1230 on February 26, 2009, and it was referred to the Committee on Energy and Commerce. 

Bill Summary

H.R. 1230 would authorize the Secretary of Health and Human Services to conduct research on acquired bone marrow failure diseases. 

 

In addition, the bill would authorize the Secretary to establish outreach and information programs targeted to minority populations affected by such diseases. 

 

Lastly, it would authorize the secretary to award grants to researchers to study best practices regarding diagnosis and care.

Background

According to the bill’s author, between 20,000 and 30,000 Americans are diagnosed each year with myelodysplastic syndromes, aplastic anemia, paroxysmal nocturnal hemoglobinuria, and other acquired bone marrow failure diseases. 

Cost

As of publication, the Congressional Budget Office had not released a score of H.R. 1230.